ゲノム編集の市場規模、シェア、成長分析、技術別、配送方法別、用途別、モード別、最終用途別、地域別 - 産業予測 2025～2032年

ゲノム編集市場規模は2023年に59億2,000万米ドルとなり、2024年の68億7,000万米ドルから2032年には226億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは16.1%で成長する見通しです。

ゲノム編集市場は、業界各社が競争上の優位性を追求する中で、緩やかなM&Aが行われています。特に、Ginkgo Bioworksが2024年1月にProof Diagnosticsを買収したことは、この動向を浮き彫りにし、同社の医療遺伝学ポートフォリオの幅を広げています。この分野の成長には、合成生物に関する政府の有利な規制、遺伝子や合成細胞に対する需要の高まり、政府や大手企業による多額の投資が寄与しています。遺伝子編集と利用のための革新的な戦略が登場し、遺伝子治療と分子生物学の進歩を促進しています。主要企業は生産性と市場参入を強化する一方、カロライナ・バイオロジカル・サプライ・カンパニーとクリスチャナケア遺伝子編集研究所が共同でCRISPR教育キットを作成するなど、専門的なイニシアチブはこの分野の認識と教育を高めることを目的としており、市場のさらなる拡大が期待されます。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 市場のエコシステム
• ケーススタディ
• 特許分析
• 規制情勢
• イノベーションマトリクス
• 主な投資の分析
• 主な成功要因
• 競合の程度

ゲノム編集市場：技術別

• 市場概要
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• その他

ゲノム編集市場：配送方法別

• 市場概要
• 生体外
• 生体内

ゲノム編集市場：用途別

• 市場概要
• 遺伝子工学
  • 細胞株工学
  • 動物遺伝子工学
  • 植物遺伝子工学
  • その他
• 臨床応用
  • 診断
  • 治療法の開発

ゲノム編集市場：モード別

• 市場概要
• 契約
• 社内

ゲノム編集市場：最終用途別

• 市場概要
• バイオテクノロジーおよび製薬会社
• 学術機関および政府調査機関
• 契約調査機関

ゲノム編集市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Merck KGaA（Germany）
• Cibus Inc（US）
• Recombinetics（US）
• Sangamo Therapeutics（US）
• Editas Medicine（US）
• Precision BioSciences（US）
• CRISPR Therapeutics（Switzerland）
• Intellia Therapeutics, Inc（US）
• Caribou Biosciences, Inc.（US）
• Cellectis S.A（France）
• AstraZeneca（UK）
• Takara Bio Inc.（Japan）
• Horizon Discovery Ltd.（Revvity, Inc.）（UK）
• Danaher Corporation（US）
• Transposagen Biopharmaceuticals, Inc.（US）
• Genscript Biotech Corp（China）
• New England Biolabs（US）
• OriGene Technologies, Inc.（US）
• bluebird bio, Inc（US）
• Lonza（Switzerland）
• Thermo Fisher Scientific, Inc.（US）

結論と提言

Genome Editing Market size was valued at USD 5.92 billion in 2023 and is poised to grow from USD 6.87 billion in 2024 to USD 22.69 billion by 2032, growing at a CAGR of 16.1% during the forecast period (2025-2032).

The Genome Editing Market is experiencing moderate merger and acquisition activity as industry players seek competitive advantages. Notably, Ginkgo Bioworks' acquisition of Proof Diagnostics in January 2024 highlights this trend, broadening its medical genetics portfolio. The sector's growth is fueled by favorable government regulations on synthetic organisms, a rising demand for genes and synthetic cells, and substantial investments from governments and major corporations. Innovative strategies for gene editing and exploitation are emerging, driving advancements in gene therapy and molecular biology. Key players are enhancing productivity and market reach while specialized initiatives, such as the collaboration between Carolina Biological Supply Company and Christianacare Gene Editing Institute to create CRISPR educational kits, aim to increase awareness and education in the field, promising further market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Genome Editing Market Segments Analysis

Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use and region. Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease and Others. Based on Delivery Method, the market is segmented into Ex-vivo and In-vivo. Based on Application, the market is segmented into Genetic Engineering, Clinical Applications. Based on Mode, the market is segmented into Contract and In-house. Based on End-use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes andContract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Genome Editing Market

The Genome Editing market is experiencing significant growth, particularly in the agricultural sector, where it's increasingly utilized to enhance crop traits such as drought resistance, pest resilience, and nutritional value. As advancements in genome editing technology continue, agriculture is poised to benefit even more from these innovations. The CRISPR technology, in particular, has revolutionized the ability to develop crops at an accelerated pace, driving demand within this market. As farmers and consumers alike seek more sustainable and nutrient-rich food options, the application of genome editing techniques will play a crucial role in shaping the future of agriculture.

Restraints in the Genome Editing Market

The Genome Editing market faces notable constraints due to ethical concerns surrounding the technology, particularly regarding its application in human embryos and bacterial cells. These ethical dilemmas have led to stringent regulatory frameworks that complicate the approval process for genome enhancement therapies, ultimately hindering market expansion. Consequently, many countries have implemented strict guidelines that act as a barrier, stalling research and development efforts in the field. As a result, the apprehension over potential misuse and the moral implications of genome editing continues to impact innovation and progress, thereby restraining the overall growth of the market.

Market Trends of the Genome Editing Market

The Genome Editing market is witnessing a significant trend driven by its expanding application in agriculture, particularly in response to global food security challenges. Technologies like CRISPR are revolutionizing crop production by enabling the creation of genetically modified crops that exhibit enhanced traits such as drought tolerance, pest resistance, and improved nutritional profiles. This rapid and precise approach to crop improvement is positioning genome editing as a key solution to meet the increasing demand for sustainable agriculture. As concerns over climate change and food scarcity intensify, genome editing technologies are expected to play a pivotal role in shaping the future of agricultural practices, significantly driving market growth.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case Studies
• Patent Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Genome Editing Market by Technology

• Market Overview
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

Genome Editing Market by Delivery Method

• Market Overview
• Ex-vivo
• In-Vivo

Genome Editing Market by Application

• Market Overview
• Genetic Engineering
  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering
  • Others
• Clinical Applications
  • Diagnostics
  • Therapy Development

Genome Editing Market by Mode

• Market Overview
• Contract
• In-house

Genome Editing Market by End-use

• Market Overview
• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations

Genome Editing Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cibus Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recombinetics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis S.A (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery Ltd. (Revvity, Inc.) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transposagen Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corp (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OriGene Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations